KCT0005928尚未招募未知
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Patients with histologically or cytologically confirmed gastric cancer, including gastric adenocarcinoma or GEJ adenocarcinoma.
- •2.Patients with metastatic or locally recurrent unresectable disease.
- •3.Patients with diseased lesions that can be measured using standard computed tomography (CT) or magnetic resonance imaging (MRI).
- •4.Patients who have experienced disease progression during or after primary therapy for metastatic disease.
- •5.Patients over 19 years of age.
- •6.All clinically significant toxic effects of previous chemotherapy, surgery, radiation therapy, or hormone therapy are rated =1 (or neuropathic Cases =2 grade) (excluding hair loss).
- •7.Patients with an Eastern Oncology Cooperative Group Performance Status (ECOG PS) score of 0 or 1.
- •8.Total bilirubin =1.5 mg/dL (25.65 µmol/L), and aspartic acid aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x upper limit of normal (ULN; or 5.0 x with liver metastasis) Patients with adequate liver function as defined by ULN).
- •9. Patients without the following conditions:
- •Child-Pugh B (or C) level of cirrhosis or
- •A history of cirrhosis (random grade) and hepatic encephalopathy or clinically significant ascites due to cirrhosis. Clinically significant ascites are defined as ascites resulting from cirrhosis and requiring diuretics or puncture.
- •10. Serum creatinine =1.5 x ULN or creatinine clearance (measured through 24-hour urine collection) =40 mL/minute (i.e., if serum creatinine is >1.5 x ULN, a 24-hour urine collection is performed to calculate the creatinine clearance rate) Patients with adequate renal function as defined by
- •11.Patients with a urine protein of =1+ on dipstick or routine urinalysis (UA) (if urine dipstick or routine analysis shows =2+ urine protein, 24 hours for protein to allow participation in this clinical trial) Urine collection should confirm that the protein is <1000 mg within 24 hours).
- •12. Patients with adequate blood function with an absolute neutrophil count (ANC) =1500/µL, hemoglobin =9 g/dL (5.58 mmol/L), and platelets =100,000/µL.
- •13.??? ?? ??? ?? (INR) =1.5 ? ?? ??????? ?? (PTT)? ULN? 5? ?? (??? ??? ?? ?? ??)? ??? ??? ?? ??? ???? ??. ??-?? ??? ??? ?? ?? ??? ??? ?? ???? ?? ???? ???? ?? ?? (??? 14? ??)? ?? ???? ??. ???? ?? ?? ???, ??? INR =3.0?? ?? ??? ??? (?, ??????? ??? ?? ?? ? 14? ??? ??? ??) ?? ?? ??? ?? ??? ?? (?: ???? ??? ?? ?? ??? ???)? ??? ??. ???? ?? ??? ?? ?? ?? ?? ??? ?? ??? ???? ??? ??? ?? ?? ??? ???? ??.
- •14.??? ?? ??? ???? ??? anthracycline ??? ?? ?? ??, ??? ?? ?? ???? ?? ???? ?? ??? ??? ? ??? ?? (?????? I?? ??? ??) (49).
- •15.???? ?? ??? ??? ?? ???? ????? ?????, ?? ???? ??? (??? ?? ???)? ?? ???? ??.
- •16.??? ?? ??? ?? ? 7? ??? ??? ?? ?? ?? ????? ??.
- •17.?? ????? ???? ??? ? ?? ??.
- •18.?? ??? ??? ?? ??.
排除标准
- •1.Patients previously receiving treatment targeting the TGF-ß signaling pathway
- •2.Patients who previously received Taxane-based chemotherapy
- •3.Patients with recorded and/or symptomatic brain or meningeal metastases.
- •4.Patients who experienced Grade 3-4 GI bleeding within 3 months prior to enrollment.
- •5.Patients who have experienced arterial thromboembolic events including, but not limited to, myocardial infarction, transient ischemic attack, cerebrovascular attack, or unstable angina within 6 months prior to enrollment.
- •6.Ongoing or active infection, symptomatic congestive heart failure, unstable angina, symptomatic or poorly controlled cardiac arrhythmias, uncontrolled thrombotic or hemorrhagic disease, interstitial pneumonia or pulmonary fibrosis, or in the judgment of the treating physician. Patients with other serious medical conditions that are not controlled.
- •7.Patients with ongoing or active psychiatric conditions or social situations that may limit adherence to treatment.
- •8.Patients with uncontrolled or poorly controlled hypertension (systolic >160 mmHg or diastolic >100 mmHg for >4 weeks) despite standard medical care.
- •9. Patients with serious or non-healing wounds, wound healing complications, ulcers, gastrointestinal perforations or fractures within 28 days prior to enrollment.
- •10. Patients who received chemotherapy, radiation therapy, immunotherapy or targeted therapy for gastric cancer within 2 weeks prior to enrollment
- •11. Patients who received other investigational drugs within 30 days prior to enrollment
- •12. Patients who have undergone major surgery within 28 days prior to enrollment or who have implanted subcutaneous vein access devices within 7 days prior to enrollment.
- •13. Patients previously receiving therapy with VEGF (including bevacizumab) or agents that directly inhibit VEGF receptor 2 activity, or with anti-angiogenic agents.
- •14. Patients on chronic antiplatelet therapy including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs; ibuprofen, naproxen and others), dipyridamole or clopidogrel or similar agents. Once daily aspirin use (maximum dose 325 mg/day) is permitted.
- •15. Patients requiring pending or scheduled surgery during the course of the clinical trial.
- •16. Patients with a known history of hypersensitivity reactions or suspected of hypersensitivity reactions to the active ingredients and excipients of investigational drugs or concomitant drugs
- •17. Pregnant or breastfeeding patients.
- •18. Patients known to be positive for human immunodeficiency virus (HIV) infection.
- •19. Patients with known alcohol or drug dependence.
- •20. Patients with active malignancies in addition to appropriately treated non-melanoma skin cancer, other non-invasive carcinoma or intraepithelial cancer.
- •21. Patients unable to take oral medication
- •22. Patients should not have received more than one line of prior therapy in a metastatic situation.
研究者
相似试验
尚未招募
2 期
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to BiomarkersGastric CancerNCT04656002Samsung Medical Center43
进行中（未招募）
2 期
TOP GEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction AdenocarcinomaA randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancerResectable Gastric CancerCancer - StomachACTRN12609000035224Australasian Gastro-Intestinal Trials Group (AGITG)574
招募中
2 期
Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR)2024-516299-13-00Centre Francois Baclesse68
进行中（未招募）
不适用
[Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus]Target-specific therapy of metastatic urothelial carcinoma with temsirolimus - Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit TemsirolimusChemotherapy refractory metastatic urothelia carcinomaMedDRA version: 9.1Level: LLTClassification code 10064467Term: Urothelial carcinomaEUCTR2008-008478-30-DEukaskrankenhaus GmbH
进行中（未招募）
不适用
Treatment of locally advanced or metastatic non-small cell lung cancer with Pemetrexed (Alimta) and Gemcitabine or Gemcitabine and Carboplatin: The PAGe study. - The PAGe studyEUCTR2005-001577-97-SEGunnar Hillerdal96